Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?

Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma; it features extreme molecular heterogeneity regardless of the classical cell-of-origin (COO) classification. Despite this, the standard therapeutic approach is still immunochemotherapy (rituximab plus cyclophosphamide, do...

Full description

Bibliographic Details
Main Authors: Nicoletta Coccaro, Luisa Anelli, Antonella Zagaria, Tommasina Perrone, Giorgina Specchia, Francesco Albano
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Cancers
Subjects:
diffuse large b-cell lymphoma (dlbcl)
coo classification
next-generation sequencing (ngs)
biomarker
liquid biopsy
targeted therapy
Online Access:https://www.mdpi.com/2072-6694/12/1/185

Internet

https://www.mdpi.com/2072-6694/12/1/185

Similar Items